David C. Metz

David C. Metz

Auto-generated profile, based on publicly available information

David C. Metz

Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1996 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
DFDouglas O. Faigel
Douglas O. Faigel
EFEmma E. Furth
Emma E. Furth
MCMarcia Childs
Marcia Childs
JGJames Goin
James Goin
DMDavid C. Metz
David C. Metz

28 September 2020 in Pancreas
Verified
Journal Article
Open access
JEJennifer R. Eads
Jennifer R. Eads
DRDiane Reidy-Lagunes
Diane Reidy-Lagunes
HSHeloisa P. Soares
Heloisa P. Soares
JCJennifer A. Chan
Jennifer A. Chan
LALowell B. Anthony
Lowell B. Anthony
FCfrom the Carcinoid Syndrome Control Collaborative
from the Carcinoid Syndrome Control Collaborative
Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience diarrhea that can have a debilitating effect on quality of life. Diarrhea also may develop in response to other hormonal syndromes associated with NETs, surgical complications, medical comorbidities, medications, or food sensitivities. Limited guidance on the practical approach to the differential diagnosis of diarrhea in these patients can lead to delays in appropriate treatment. This clinical review and commentary underscore the complexity in identifying the etiology of diarrhea in patients with NETs. Based on our collective experience and expertise, we offer a practical algorithm to guide medical oncologists and other care providers to expedite effective management of diarrhea and related symptoms in patients with NETs.

1 October 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
DMDavid C Metz
David C Metz
ELEric Liu
Eric Liu
VJVijay N Joish
Vijay N Joish
LHLynn Huynh
Lynn Huynh
Todor I. TotevTodor I. Totev
Todor I. Totev
MMMichael A Morse
Michael A Morse
Purpose: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. Patients and Methods: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. Results: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7– 39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8– 39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. Conclusion: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size.

8 June 2020 in Techniques and Innovations in Gastrointestinal Endoscopy
Verified
Journal Article
Open access
SKShria Kumar
Shria Kumar
DMDavid C. Metz
David C. Metz
VCVinay Chandrasekhara
Vinay Chandrasekhara
DKDavid Edward Kaplan
David Edward Kaplan
DGDavid S. Goldberg
David S. Goldberg
Recent studies show promise for endoscopic submucosal dissection (ESD) in the US, but do not identify the potential impact of ESD among newly diagnosed gastric cancers. We utilize the Veterans Health Administration to identify cancers suitable for ESD, to define the role of ESD in the US. Retrospective cohort study using the Veterans Affairs Central Cancer Registry to identify patients with gastric cancer who underwent surgical resection from 1995–2018. TNM stage was used to categorize those who would meet absolute vs expanded indications for ESD. Primary outcome was lymph node status. Secondary analysis was performed with death as outcome. Of 12,584 primary gastric cancers, 4,735 (37.6%) were non-metastatic gastric adenocarcinomas. Median age at diagnosis was 70.3 years, 4,676 (98.8%) male. 2,306 (48.7%) underwent surgical resection, of which 636 (27.6%) were T1 lesions or cancer in situ. Of these, 44 (6.9%) met absolute indications for resection, 99 (15.6%) met established expanded criteria, and 98 (15.4%) may meet expanded criteria. Half of all tumors in each group were proximal in location. Rate of lymph node positivity was: 4.5%; 95% CI:0.5–15.5% in absolute group; 8.1%; 95% CI:3.6–15.3% in expanded group; 13.3%; 95% CI:7.3–21.6 in those potentially meeting expanded criteria. Lymph nodes positivity was associated with death (HR 1.49; 95% CI:1.36–1.62, p<0.001). Less than 10% of T1 or in situ cancers meet absolute criteria for ESD. Those that meet expanded criteria had higher risk for lymph node metastases, particularly proximal tumors. Future studies should evaluate the safety of ESD in proximal gastric tumors.

1 August 2019 in Gastroenterology
Verified
Journal Article
Open access
JNJeri Nieves
Jeri Nieves
MPMaria Claudia Perez
Maria Claudia Perez
DMDavid C. Metz
David C. Metz
KHKaren E. Hansen
Karen E. Hansen

1 January 2021
Verified
Book
Closed access
PDF file
DMDavid Metz
David Metz
SPShannon Prier
Shannon Prier
BMBenjamin M. Miller
Benjamin M. Miller
Occupational heat exposure can result in lost productivity, illness, injury, and death. This report is a standardized regulatory impact assessment for the California Department of Industrial Relations' indoor heat illness prevention regulation.